There are currently 83 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT05400122
Recruiting
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma
Register for Updates
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
NCT04187703
Recruiting
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bone marrow function is believed to result from abnormalities that prevent the normal maturation process by which bone marrow cells develop into red blood cells, white blood cells and platelets. In myelod... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
Register for Updates
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
NCT05350748
Recruiting
Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease. Eligibility: People with suspected or confirmed MDS or MDS/MPN. Healthy do... Read More
Gender:
All
Ages:
Between 1 day and 120 years
Trial Updated:
06/21/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myelodysplastic Syndromes
Register for Updates
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
NCT05588154
Recruiting
Background: Myelodysplastic syndromes (MDS) are disorders of blood stem cells that can develop into blood cancers. Treatment options are limited. To find better treatments, researchers need to better understand how MDS develops. To do that, they must be able to compare biospecimens from people with the disease to those of healthy people. Objective: This study will create a database of biospecimens collected from healthy volunteers. Eligibility: Healthy people aged 18 and older. Design: Pa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myelodysplastic Syndromes
Register for Updates
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
NCT05968963
Recruiting
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Miami, Miami, Florida
Conditions: Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
NCT06021600
Recruiting
To compare an investigational oral form of the drug cladribine to the FDA approved form of the drug when it is given by vein (IV).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Register for Updates
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +62 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Community Cancer Institute, Clovis, California +139 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT05796570
Recruiting
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: Decitabine (a nucleoside metabolic inhibitor) Filgrastim (a recombinant granulocyte colony-stimulating fa... Read More
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
06/14/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
Register for Updates
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
NCT03810196
Recruiting
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.
Gender:
All
Ages:
25 years and below
Trial Updated:
06/13/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
Register for Updates
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
NCT02211755
Recruiting
Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and efficacy of the drug combination of bortezomib and clofarabine. Eligibility: - Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy. Design: Participants will be screened w... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/12/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: City of Hope, Duarte, California +12 locations
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates